An observational study in Fibrosarcoma, sponsored by asmaa salama ibrahim. Completed at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2024-10-29.
Sponsored by asmaa salama ibrahim · Observational
Fibrosarcoma is a malignant tumor originating from mesenchymal tissues and consists of fibroblasts with various types of collagen production. It represents 10% of musculoskeletal sarcomas and less than 5% of all primary bone tumors. It affects middle-aged patients with the most common location in the femur and 70% long tubular bones. Studies reported that fibrosarcoma patients tend to develop a subsequent primary malignancy, the analysis showed a higher risk of SPMs even a decade following the initial diagnosis of fibrosarcoma.
SPMs affect the long-term survival of patients with soft tissue tumors, and since there are no available studies analyzing the risk of second primary malignancies in different types of fibrosarcomas, especially the infantile and adult-type. Therefore, the purpose of this study was to assess the risk of second primary malignancies following primary fibrosarcoma diagnosis for a better understanding of the nature of this rare neoplasm. The investigators used the Surveillance, Epidemiology and End Results (SEER) database to extract the data and calculate the standardized incidence ratio as Observed/Expected and the Excess risk for second primary malignancies with 95% Confidence Interval. Significance was achieved at 0.05.
69 studies on the registry are indexed under Fibrosarcoma; 7 are open to participants now.
Browse Fibrosarcoma studies →asmaa salama ibrahim is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study included 12,783 patients diagnosed with fibrosarcoma between 2000 and 2021.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Infantile fibrosarcoma, Fibromyxosarcoma, Periosteal fibrosarcoma, Facial fibrosarcoma, Dermatofibrosarcoma, Central odontogenic fibrosarcoma, Ameloblastic fibrosarcoma
Exclusion Criteria:
The standardized incidence ratio and excess risk of developing multiple primary malignancies following fibrosarcoma diagnosis
The surveillance, epidemiology and End Results (SEER) database was used to calculate the standardized incidence ratio (SIR) as Observed/Expected (O/E) and calculated the Excess absolute risk for Multiple primary malignancies for fibrosarcoma patients
Time frame: from Jan, 2000 till Dec, 2021
The standardized incidence ratio and excess risk of developing second primary malignancies for different subtypes of fibrosarcoma
Time frame: from Jan, 2000 till Dec, 2021
The standardized incidence ratio and excess risk of multiple primary malignancies in fibrosarcoma patients across different racial groups
Time frame: from Jan, 2000 till Dec, 2021
The standardized incidence ratio and excess risk of multiple primary malignancies in both males and females in fibrosarcoma patients
Time frame: from Jan, 2000 till Dec, 2021
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2000 to primary completion in Dec 2021, 263 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
asmaa salama ibrahim